View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
TUESDAY, Sept. 6 (HealthDay News) -- Immunoadsorption of immunoglobulin G (IgG) antibodies can safely be used to treat neurological complications in patients with Escherichia coli (E. coli) O104:H4-induced hemolytic uremic syndrome (HUS), according to a study published online Sept. 5 in The Lancet.
Andreas Greinacher, M.D., from the Institut für Immunologie und Transfusionmedizin in Greifswald, Germany, and colleagues investigated the use of immunoadsorption for the treatment of post-enteritis HUS and thrombotic microangiopathy in 12 patients with severe neurological symptoms and recently confirmed E. coli O104:H4 infection. IgG immunoadsorption processing of 12 L plasma volumes was performed on two consecutive days followed by 0.5 g/kg intravenous IgG replacement. Composite neurological symptom score was calculated daily and changes before and after immunoadsorption were evaluated.
The investigators found that renal replacement therapy was required by 10 of the 12 patients in a median of eight days. Neurological complications were observed at a median of eight days, and necessitated mechanical ventilation in nine patients. The composite neurological symptom scores improved significantly, from 3.0 in the three days before immunoadsorption to 1.0 three days afterward. Improvement was observed (disappearance of aphasia) in non-intubated patients during immunoadsorption. Among the nine patients who were intubated, five were weaned within 48 hours, two within four days, and two continued ventilation for respiratory problems. All 12 patients survived and 10 experienced complete neurological and renal function recovery.
"Our study is the first to show effectiveness of immunoadsorption for treatment of severe neurological complications related to E. coli 0104:H4 hemolytic uremic syndrome," the authors write.
Two authors disclosed financial ties to Fresenius Medical Care.
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top